Abstract Body

Several pharmaceutical compounds as the Latency reversal agents (LRAs) can reactivate HIV expression from infected cells and might help to reduce the pool of latently infected CD4 T cells. However, the capacity of the LRAs to reactivate all infected CD4 T subpopulations is currently unknown.

Viral reactivation assays were performed using freshly-isolated CD4+T cells obtained from whole blood donations of n=9 ART-suppressed patients. A total of 13 conditions, including controls, Ingenol (ING) and Bryostatin-1 (BRY) (PKC agonists), Romidepsin (RMD) and Panobinostat (PNB) (HDAC inhibitors) and JQ1 (Bromodomain inhibitor), and the combinations of LRAs from different families, were set up per patient. Intracellular HIV-RNA and p24 production were evaluated by the flow-RNA/FISH technology within different CD4+T cell subsets (Naïve-NA; Stem Cell Memory-SCM; Central Memory-CM, Effector memory-EM; Transitional Memory-TM and Terminally Differentiated-TD) after 22h in culture. Synergies and antagonisms between compounds were calculated using the Bliss independence model.

In general, a median of 10.74% of the whole HIV-reservoir in CD4+T cells induced HIV-RNA after viral reactivation but only 10.1% of these reactivated cells produced p24. The highest levels of HIV-RNA and the viral protein p24 were induced by ING, RMD and PNB followed by BRY and JQ1. Moreover, the combination of RMD+ING induced a reactivation of 3.50-fold compared to negative control. Regarding CD4+T subpopulations, most memory subsets were reactivated by Romidepsin and the highest susceptibility was observed in the TEM cells (FC=4.24). PNB was more efficient at reactivating TCM (FC=2.11) and TEM cells (FC=2.32), and ING was performing better in TCM (FC=4.05) and TTM (FC=5.27) but not in TEM cells. For combinations of LRAs, RMD+ING became the most effective condition in all tested CD4+T cell subsets, primarily in TTM (FC=6.72), but with no effect in TSCM. Contrarily, an antagonistic effect in terms of HIV transcription was observed when PNB+ING were added.

Our results validate the use of the flow-RNA/FISH protocol to assess the potency of LRAs in different CD4+T cell subsets. Although important synergies are identified when RMD and ING are combined, existing LRAs present limited capacity to induce HIV transcription in the most important reservoir cells. This study emphasizes the need to generate new drugs with wide reactivation ability in all CD4+T cells for future clinical trials.